Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  carfilzomib
Find trials that include:  Any drugs shown
Results 1-25 of 40 for your search:
Start Over
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ014, NCI-2015-01208, 2014-005325-12, NCT02412878
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201102043, NCI-2011-00224, NCT01246063
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AMyC 10-MM-01, NCI-2012-01279, IST-CAR-521, PO-MM-PI-0034, NCT01464034
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1088, NCI-2012-01168, MMRC# 044, NCT01665794
Carfilzomib and High-Dose Melphalan Before Stem Cell Transplant in Treating Patients with Relapsed Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 101669, NCI-2012-00836, CTO 101669, MUSC CTO#: 101669, MUSC/Onyx IST-CAR-536, Onyx #: IST-CAR-536, Pro00014849, NCT01690143
Carfilzomib, Lenalidomide and Rituximab in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0188, NCI-2014-01201, NCI-2013-00117, NCT01729104
Carfilzomib and Melphalan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1185, NCI-2013-00550, NCT01842308
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 74
Trial IDs: I 240813, NCI-2013-01784, NCT01959698
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1119-CA, NCI-2014-00660, PCI-32765 [Sponsor], NCT01962792
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ004, NCI-2014-01347, 2013-002597-44, NCT01987232
Carfilzomib in Combination with Bendamustine Hydrochloride and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ2359, NCI-2014-02521, IRB-AAAJ2359, NCT02002598
Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CFZ008, NCI-2014-02601, 2014-001633-84, NCT02303821
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Smoldering Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0107, NCI-2013-01514, 120107, P11899, RV-MM-NCI-0719, NCT01572480
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro 3596 (CAR-531), NCI-2015-00009, NCT01813227
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1725, NCI-2012-02023, NCT01816971
Carfilzomib and Dexamethasone for Treating Patients with Relapsed or Refractory Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1304, NCI-2013-00796, PS1304_A07PAMDREVW01, SWOG-S1304, NCT01903811
Carfilzomib in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0259, NCI-2014-01271, NCT02042950
Carfilzomib in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer That Has Progressed after Chemotherapy and Androgen Inhibitor Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1336, NCI-2015-00263, F130725012, NCT02047253
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TG02-101, NCI-2010-02048, NCT01204164
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0733, NCI-2011-00316, NCT01301807
Carfilzomib in Treating Patients with Relapsed or Refractory T-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 518-10, NCI-2010-02257, NCT01336920
Start Over